Gregori-Puigjané, E. et al. Identifying mechanism-of-action targets for drugs and probes. Proc. Natl Acad. Sci. USA 109, 11178–11183 (2012).
Emmerich, C. H. et al. Improving target assessment in biomedical research: the GOT-IT recommendations. Nat. Rev. Drug Discov. 20, 64–81 (2021).
Vincent, F. et al. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat. Rev. Drug Discov. 21, 899–914 (2022).
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat. Rev. Drug Discov. 16, 531–543 (2017).
Corsello, S. M. et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer 1, 235–248 (2020).
Pemovska, T. et al. Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. Nat. Commun. 12, 7190 (2021).
Subramanian, A. et al. A next generation Connectivity Map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437–1452 (2017).
Way, G. P. et al. Morphology and gene expression profiling provide complementary information for mapping cell state. Cell Syst. 13, 911–923 (2022).
Mitchell, D. C. et al. A proteome-wide atlas of drug mechanism of action. Nat. Biotechnol. 41, 845–857 (2023).
Messner, C. B. et al. Ultra-fast proteomics with Scanning SWATH. Nat. Biotechnol. 39, 846–854 (2021).
Anglada-Girotto, M. et al. Combining CRISPRi and metabolomics for functional annotation of compound libraries. Nat. Chem. Biol. 18, 482–491 (2022).
Zecha, J. et al. Decrypting drug actions and protein modifications by dose- and time-resolved proteomics. Science 380, 93–101 (2023).
Filzen, T. M., Kutchukian, P. S., Hermes, J. D., Li, J. & Tudor, M. Representing high throughput expression profiles via perturbation barcodes reveals compound targets. PLoS Comput. Biol. 13, e1005335 (2017).
Feng, Y., Mitchison, T. J., Bender, A., Young, D. W. & Tallarico, J. A. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat. Rev. Drug Discov. 8, 567–578 (2009).
Kang, J. et al. Improving drug discovery with high-content phenotypic screens by systematic selection of reporter cell lines. Nat. Biotechnol. 34, 70–77 (2016).
Badwan, B. A. et al. Machine learning approaches to predict drug efficacy and toxicity in oncology. Cell Rep. Methods 3, 100413 (2023).
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science 363, eaat9931 (2019).
Gonçalves, E. et al. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell 40, 835–849 (2022).
Frejno, M. et al. Proteome activity landscapes of tumor cell lines determine drug responses. Nat. Commun. 11, 3639 (2020).
Cohen, A. A. et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511–1516 (2008).
van’t Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature 568, 511–516 (2019).
Douglass, E. F. et al. A community challenge for a pancancer drug mechanism of action inference from perturbational profile data. Cell Rep. Med. 3, 100492 (2022).
Nair, N. U. et al. A landscape of response to drug combinations in non-small cell lung cancer. Nat. Commun. 14, 3830 (2023).
Bansal, M. et al. A community computational challenge to predict the activity of pairs of compounds. Nat. Biotechnol. 32, 1213–1222 (2014).
Duran-Frigola, M. et al. Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker. Nat. Biotechnol. 38, 1087–1096 (2020)
Ortmayr, K., Dubuis, S. & Zampieri, M. Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism. Nat. Commun. 10, 1841 (2019).
Dubuis, S., Ortmayr, K. & Zampieri, M. A framework for large-scale metabolome drug profiling links coenzyme A metabolism to the toxicity of anti-cancer drug dichloroacetate. Commun. Biol. 1, 101 (2018).
Brunk, E. et al. Recon3D enables a three-dimensional view of gene variation in human metabolism. Nat. Biotechnol. 36, 272–281 (2018).
Wishart, D. S. et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res. 46, D608–D617 (2018).
Campos, A. I. & Zampieri, M. Metabolomics-driven exploration of the chemical drug space to predict combination antimicrobial therapies. Mol. Cell 74, 1291–1303 (2019).
Blasi, F., Sommariva, D., Cosentini, R., Cavaiani, B. & Fasoli, A. Bezafibrate inhibits HMG-CoA reductase activity in incubated blood mononuclear cells from normal subjects and patients with heterozygous familial hypercholesterolaemia. Pharmacol. Res. 21, 247–254 (1989).
Elis, J. & Rašková, H. New indications for 6-azauridine treatment in man. A review. Eur. J. Clin. Pharmacol. 4, 77–81 (1972).
González-Aragón, D., Ariza, J. & Villalba, J. M. Dicoumarol impairs mitochondrial electron transport and pyrimidine biosynthesis in human myeloid leukemia HL-60 cells. Biochem. Pharmacol. 73, 427–439 (2007).
Cao, S. et al. Tiratricol, a thyroid hormone metabolite, has potent inhibitory activity against human dihydroorotate dehydrogenase. Chem. Biol. Drug Des. 102, 1–13 (2023).
Lyu, J. et al. Ultra-large library docking for discovering new chemotypes. Nature 566, 224–229 (2019).
Diao, Y. et al. Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening. J. Med. Chem. 55, 8341–8349 (2012).
Chilingaryan, G. et al. Combination of consensus and ensemble docking strategies for the discovery of human dihydroorotate dehydrogenase inhibitors. Sci. Rep. 11, 11417 (2021).
Wierbowski, S. D., Wingert, B. M., Zheng, J. & Camacho, C. J. Cross-docking benchmark for automated pose and ranking prediction of ligand binding. Protein Sci. 29, 298–305 (2020).
Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455–461 (2010).
Corso, G. et al. Deep confident steps to new pockets: strategies for docking generalization. Preprint at arXiv https://doi.org/10.48550/arXiv.2402.18396 (2024).
Mysinger, M. M., Carchia, M., Irwin, J. J. & Shoichet, B. K. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 55, 6582–6594 (2012).
Bender, B. J. et al. A practical guide to large-scale docking. Nat. Protoc. 16, 4799–4832 (2021).
Hwangbo, H., Patterson, S. C., Dai, A., Plana, D. & Palmer, A. C. Additivity predicts the efficacy of most approved combination therapies for advanced cancer. Nat. Cancer 4, 1693–1704 (2023).
Hardy, R. S., Raza, K. & Cooper, M. S. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat. Rev. Rheumatol. 16, 133–144 (2020).
Caratti, B. et al. The glucocorticoid receptor associates with RAS complexes to inhibit cell proliferation and tumor growth. Sci. Signal. 15, eabm4452 (2022).
Snijder, B. et al. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 4, e595–e606 (2017).
Gonçalves, E. et al. Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens. Mol. Syst. Biol. 16, e9405 (2020).
Breinig, M., Klein, F. A., Huber, W. & Boutros, M. A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells. Mol. Syst. Biol. 11, 846 (2015).
di Bernardo, D. et al. Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nat. Biotechnol. 23, 377–383 (2005).
Carraro, C. et al. Decoding mechanism of action and sensitivity to drug candidates from integrated transcriptome and chromatin state. eLife 11, e78012 (2022).
Franken, H. et al. Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nat. Protoc. 10, 1567–1593 (2015).
Piazza, I. et al. A machine learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes. Nat. Commun. 11, 4200 (2020).
Ye, C. et al. DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery. Nat. Commun. 9, 4307 (2018).
Sinha, S., Sinha, N. & Ruppin, E. Deep characterization of cancer drugs mechanism of action by integrating large-scale genetic and drug screens. Preprint at bioRxiv https://doi.org/10.1101/2022.10.17.512424 (2022).
Stokes, J. M. et al. A deep learning approach to antibiotic discovery. Cell 180, 688–702 (2020).
Cappelletti, V. et al. Dynamic 3D proteomes reveal protein functional alterations at high resolution in situ. Cell 184, 545–559 (2021).
Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457–D462 (2016).
Okimoto, R. A. et al. Inactivation of Capicua drives cancer metastasis. Nat. Genet. 49, 87–96 (2017).
Ortmayr, K. & Zampieri, M. Sorting-free metabolic profiling uncovers the vulnerability of fatty acid β-oxidation in in vitro quiescence models. Mol. Syst. Biol. 18, e10716 (2022).
Zimmermann, M., Sauer, U. & Zamboni, N. Quantification and mass isotopomer profiling of α-keto acids in central carbon metabolism. Anal. Chem. 86, 3232–3237 (2014).
Storey, J. D. A direct approach to false discovery rates. J. R. Stat. Soc. Ser. B Stat. Methodol. 64, 479–498 (2002).
Sunseri, J. & Koes, D. R. Virtual screening with Gnina 1.0. Molecules 26, 7369 (2021).
